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Abstract
Our previous studies have shown that overexpression of bovine FcRn (bFcRn) in transgenic (Tg) mice leads to an increase in
the humoral immune response, characterized by larger numbers of Ag-specific B cells and other immune cells in secondary
lymphoid organs and higher levels of circulating Ag-specific antibodies (Abs). To gain additional insights into the
mechanisms underlying this increase in humoral immune response, we further characterized the bFcRn Tg mice. Our
Western blot analysis showed strong expression of the bFcRn transgene in peritoneal macrophages and bone marrow
derived dendritic cells; and a quantitative PCR analysis demonstrated that the expression ratios of the bFcRn to mFcRn were
2.6- and 10-fold in these cells, respectively. We also found that overexpression of bFcRn enhances the phagocytosis of Ag-
IgG immune complexes (ICs) by both macrophages and dendritic cells and significantly improves Ag presentation by
dendritic cells. Finally, we determined that immunized bFcRn mice produce a much greater diversity of Ag-specific IgM,
whereas only the levels, but not the diversity, of IgG is increased by overexpression of bFcRn. We suggest that the increase
in diversity of IgG in Tg mice is prevented by a selective bias towards immunodominant epitopes of ovalbumin, which was
used in this study as a model antigen. These results are also in line with our previous reports describing a substantial
increase in the levels of Ag-specific IgG in FcRn Tg mice immunized with Ags that are weakly immunogenic and, therefore,
not affected by immunodominance.
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Introduction
The production of monoclonal antibodies (mAbs) using
hybridoma technology has allowed significant advances in
biomedical research and has greatly improved our capacity for
clinical diagnostics and therapeutics. Currently, more than 25
immunoglobulins have been approved for therapeutical use in
humans and over 240 antibodies are in development targeting a
wide variety of diseases, including autoimmunity, cancer, infec-
tious diseases and cardiovascular diseases (reviewed by [1]).
In recent years, there has been an increasing demand for the
development of cheaper, faster and more efficient technologies for
the production of high-affinity and high-specificity mAbs. One
approach to improve the efficiency of hybridoma production is to
enhance humoral immune response against various antigens (Ags),
including weakly immunogenic targets to which mAbs are
generally difficult to generate. Another approach is to create a
higher diversity of Ag-specific antibodies, allowing for the
development of a larger variety of hybridomas, which can be
screened for their ability to bind native epitopes and to produce
functionally relevant mAbs [2]. To achieve these goals, our group
has recently created transgenic (Tg) mice that overexpress the
bovine neonatal Fc receptor (bFcRn) [3] and show a greatly
augmented humoral immune response. Our previous analyses
have shown that the bFcRn Tg mice offer major advantages for
hybridoma production and could serve as important tools for the
development of new therapeutic mAbs [4]. In addition, we have
recently generated Tg rabbits that overexpress the rabbit FcRn
and observed similarly improved IgG protection and enhanced
humoral immune response as described for bFcRn Tg mice [5].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36286The neonatal Fc receptor (FcRn) is a MHC Class I-related
receptor composed of an a-chain and b2-microlobulin (b2m) [6]
and was originally identified as the protein that mediates the
transport of IgG from maternal milk to the small intestine of
newborn rodents [7]. FcRn has proven to be a key player in
regulating the transport of IgG within and across cells of diverse
origins and it also serves to rescue IgG and albumin from
degradation, thereby prolonging their half-lives [8]. IgG protec-
tion was originally thought to be mediated by capillary endothelial
cells [9] but recent findings suggest that this process also occurs in
hematopoietic cells [10,11] and in mammary epithelial cells during
lactation [12]. More recently, several publications have shown that
FcRn plays major roles in Ag-IgG immune complex (IC)
phagocytosis by neutrophils [13], and in Ag presentation of IgG
ICs by professional Ag presenting cells (APCs) [14,15,16,17].
We have recently shown that overexpression of bFcRn in Tg
mice leads to increased levels of IgG in the serum as a result of a
reduction in IgG catabolism. In addition, we found that expression
of bFcRn in Tg mice causes an increase in the levels of Ag-specific
IgG and IgM during the secondary immune response and leads to
an enhanced expansion of Ag-specific B cells and plasma cells in
their spleen [18,19]. We also observed that, upon immunization,
bFcRn Tg mice develop enlarged spleens that contain higher
numbers of neutrophil granulocytes and dendritic cells (DCs) as
compared to wild-type (wt) mice [18,20]. This augmented immune
response is also reflected in the ability of bFcRn Tg mice to
produce high levels of Ag-specific antibodies, B cells and plasma
cells to weakly immunogenic targets [20] and to produce elevated
numbers of Ag-specific hybridomas [19].
To better understand the mechanisms underlying the augment-
ed humoral immune response observed in bFcRn Tg mice, we
further characterized the profile of bFcRn transgene expression in
different cells of the immune system. In addition, we investigated
the effects of overexpression of bFcRn in the phagocytic activity of
macrophages and dendritic cells, as well as its effect on Ag-
presentation by dendritic cells. Moreover, we investigated whether
the enhanced immune response in bFcRn Tg mice correlates with
an increase in the diversity of Ag-specific immunoglobulins.
Materials and Methods
Ethics statement
All the treatments of animals (mice) in this research followed the
guidelines of the Institutional Animal Care and Ethics Committee
at Eo ¨tvo ¨s Lora ´nd University that operated in accordance with
permissions 22.1/828/003/2007 issued by the Central Agricul-
tural Office, Hungary and all animal work was approved by the
appropriate committee.
Mice
We used hemizygous transgenic mice that carry five copies of
the bovine FcRn a-chain encoding gene (bovine FCGRT) in
addition to the endogenous mouse FCGRT gene on BALB/c
genetic background (BALB/c_Tg5_bFCGRT(19); 19 refers to the
founder line) we have previously generated [18]. As controls, we
used wt littermates and standard BALB/c mice. Tg and wt mice
were used for peritoneal macrophage isolation (10-week old), bone
marrow derived dendritic cell generation (4–8 week old), cell-
specific bFcRn detection and epitope mapping (female mice; 8–10
week old). For T cell proliferation assays, we used mice carrying
the MHC class II restricted rearranged T cell receptor transgene
Tg(DO11.10)10Dlo, which binds to ovalbumin (OVA) peptide
antigen (OVA 323–339 peptide) purchased from The Jackson
Laboratory (Bar Harbor, ME, USA).
Cells
Isolation of splenic B-cells, T-cells. Isolation of splenic B-
cells, T-cells splenocytes were incubated with fluorochrome-
conjugated specific Abs at 4uC for 50 min in PBS and subjected
to cell sorting using FACSAria III cell sorter (BD Biosciences,
Franklin Lakes, NJ, USA) equipped with FACSDiva v6.1.3
software. Phycoerythrin (PE)-labeled anti CD3-(eBioscience, San
Diego, CA, USA) and FITC-labeled anti CD19 (eBioscience) were
used to isolate T cells and B cells, respectively.
Isolation of peritoneal neutrophil granulocytes. Isolation
of peritoneal neutrophil granulocytes mice were injected i.p. with
1 ml of 10 mg/ml casein (Sigma-Aldrich, Budapest, Hungary) in
sterile saline. The procedure was repeated 12 hours later and
peritoneal cells were isolated 3 hours after the second injection.
Neutrophils were then further purified by Ficoll-Paque PLUS (GE
Healthcare, Uppsala, Sweden) centrifugation (4006g for 30 min
at RT) and its purity was determined by flow cytometry using
Alexa Fluor 647-labeled anti-CD11b (eBioscience) and PE-labeled
anti-Gr-1 (BD Pharmingen) reagents.
Isolation of peritoneal macrophages. Isolation of
peritoneal macrophages mice were injected i.p. with 1 ml of 3%
Brewer thioglycolate medium, euthanized 3 days later and the
peritoneal exudate cells were harvested. The purity of peritoneal
macrophages was determined with Alexa Fluor 647-labeled anti-
CD11b and PE-labeled anti-Gr1.
Differentiation of dendritic cells from bone
marrow. Differentiation of dendritic cells from bone marrow
bone marrow cells were isolated from femurs and tibias and
cultured at 2610
6 cells/ml in 6-well cell culture dishes containing
2 ml of RPMI II, 10% FCS, 10 ng/ml rmGM-CSF (Millipore,
Billerica, MA, USA) and 10 ng/ml rmIL4 (eBioscience). Two-
thirds of the media were replaced every 2 days. After 7 days of
treatment, the differentiated dendritic cells were stained by using
PE-labeled anti-MHCII (I-A/I-E) (eBioscience), Alexa Fluor 647-
labeled anti-CD11b, PE-labeled anti-CD11c (BD Pharmingen),
PE-labeled anti-Gr1 (Ly6-G) (BD Pharmingen), and FITC-labeled
anti-CD14 (BD Pharmingen) and analyzed by flow cytometry. We
also analyzed the expression of the FccRs with K9.361 [21], MHC
class II with M5/114 (TIB120; ATCC, USA) and B7.1 with
1610A [22] and B7.2 with HB-253 (GL1, ATCC) on these cells.
Isotype controls were obtained from BD Pharmingen or
eBioscience.
bFcRn detection by Western blot analysis
Generation of bFcRn-specific monoclonal
antibody. Generation of bFcRn-specific monoclonal antibody
2 month old female BALB/c mice were immunized with 50 mg
soluble bFcRn (sbFcRn) molecule [23] in CFA intraperitoneally
(i.p.) and boosted two times with 3 week intervals with 50 mg
sbFcRn in IFA i.p. On day 63, 25 mg sbFcRn was given
intravenously and the same amount i.p. Fusion and hybridoma
selection were performed under the same conditions as described
earlier [19]. Hybridoma microculture supernatants were first
screened in a sbFcRn specific ELISA assay; then the positive
clones were further tested in Western blots and finally a positive
microculture was selected for cloning using limiting dilution
method, resulting in a bFcRn-specific clone (1E5/2).
Western blot. Spleen, splenic B-cells, T-cells, peritoneal
neutrophil granulocytes, peritoneal macrophages and bone
marrow derived dendritic cells from bFcRn Tg mice as well as
spleen from control (BALB/c) mice were lysed, and their protein
concentrations were determined by Micro BCA Protein Assay kit
(Pierce Biotechnology, Rockford, IL, USA). 20 and 5 mgo f
peritoneal macrophages and bone marrow derived dendritic cells
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granulocytes were subjected to electrophoresis on 10% SDS-PAGE
gel and transferred to Immobilon P PVDF membrane (Millipore,
Billerica, MA, USA). Blot was probed with the supernatant of our
mouse anti-bFcRn specific monoclonal antibody (1E5/2; conc:
26 mg/ml) according to standard protocol. bFcRn a-chain protein
was detected with horseradish peroxidase-conjugated goat anti-
mouse IgG antibody (Southern Biotech, Birmingham, AL, USA)
and enhanced chemiluminescence, using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL,
USA).bFcRnstable-transfectedbovinemammaryepithelialcellline
B4 [23] was used as positive control. The same blot was
rehybridized with anti-b-actin monoclonal antibody as loading
control.
bFcRn and mouse FcRn (mFcRn) a-chain gene expression
in spleen, peritoneal macrophages, and bone marrow
derived dendritic cells
Total RNA was extracted by using RNeasyH Plus Mini Kit (that
includes a DNase digestion step, Qiagen GmbH, Germany) from
spleen, peritoneal macrophages, and bone marrow derived
dendritic cells of transgenic mice and first strand of cDNA was
synthesized using the High Capacity cDNA Reverse Transcription
Kit (Life Technologies, USA). Quantitative PCR was run with
RotorGene RG-3000 (RotorGene software, Corbett Research,
Sidney, Australia). Relative quantifications with efficiency correc-
tion of the individual transcripts were determined according to the
mathematical model described earlier [24]. PrimeTime double
quenched assays (Integrated DNA Technologies, Coralville, Iowa,
IA, USA) using primer and probe sets for bFcRn, mFcRn and
mouse polyubiquitin-B (to normalize qRT-PCR data) (Table 1)
were performed. Samples contained 100 ng DNA per PCR
reaction which was initiated with a denaturation step at 95uC
10 min, followed by 40 cycles of 95uC 15 sec, 60uC 60 sec.
Confocal microscopy
For confocal imaging we used an Olympus Fluoview 500
confocal microscope (Hamburg Germany) equipped with four
optical channels and a 606 (numerical aperture of 1.45) oil
immersion objective.
Phagocytosis assay
For the phagocytosis assays, we used an Alexa Fluor 488-labeled
IC that contains Alexa Fluor 488-labeled OVA and anti-OVA
IgG. The anti-ovalbumin IgG was purified from sera of OVA
immunized mice. 10 mg/well of IC or soluble OVA were added to
5610
5 bone marrow-derived DCs and 5610
5 peritoneal macro-
phages. Cells were incubated at 37uC and 5% CO2 for 30, 60, 90,
and 120 min. As controls, cells were incubated with either IC or
OVA on ice. After phagocytosis, cells were washed at 4uC and the
bone marrow-derived DCs were labeled with PE-labeled anti-
MHCII (I-A/I-E), and Alexa Fluor 647-labeled anti-CD11b, while
the peritoneal macrophages were labeled with Alexa Fluor 647-
labeled anti-CD11b and PE-labeled anti-Gr1 (Ly6-G). Samples
were analyzed by flow cytometry and confocal microscopy.
T-cell proliferation assay
Bone marrow-derived DCs were added to 96-well plates (2610
5
DC/well) and were left untreated or incubated with either IC or
soluble OVA (100 mg/ml) for 1 hour at 37uC and 5% CO2.
Mouse CD4
+ T cells from DO11.10 mice bearing an OVA-
reactive transgenic TCR were purified by negative selection with
CD8
+ and CD19
+ microbeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany). Purified CD4
+ T cells (4610
5 cells/well) were
then added to the untreated, IC- or OVA–treated bone marrow-
derived DCs. As a positive control, T cells were treated with 1 mg/
ml of Concanavalin A (ConA) (Sigma-Aldrich, St. Louis, MO,
USA). Cells were incubated at 37uC, 5% CO2 for 24 hours and
then labeled with 37 kBq [H3]-thymidine for 12 hours. T cell
proliferation was determined by [H3]-thymidine incorporation.
Ovalbumin (OVA) immunizations and ELISA
15 BALB/c_Tg5_bFCGRT (19) and 15 wt control mice were
immunized i.p. with 200 mg OVA in Complete Freund Adjuvant
(CFA) and challenged i.p. with 50 mg OVA in Incomplete Freund
Adjuvant (IFA) on days 21 and 42. Animals were bled on days 0,
21, 28, 42 and 49; sera were harvested and stored in aliquots at
220uC until use. Ag-specific immunoglobulin (IgG and IgM) titers
were measured by ELISA as described before [18].
Microarray preparation
Based on the sequence of OVA (NCBI Reference Sequence:
NP_990483.1), an overlapping library of 95 12-mer peptides was
synthesized by JPT Peptide Technologies (Berlin, Germany).
Peptides that cover the whole sequence of OVA with an offset of 4
amino acids and an overlap of 8 amino acids were biotinylated on
their N-terminus and mixed with streptavidin at a 1:4 molar
concentration (Figure S1). Peptide-streptavidin complexes were
Table 1. Sequences of PrimeTime PCR primer/probe sets used to measure the expression of bFcRn, mFcRn and mouse
poliubiquitin.
Target Reference sequence in GenBank Primer and probe sequences
bFcRn NM_176657 F-59-TCTCCTTCTACCCACCTGAG-39
R-59-GTCTATCTCACCAGAGCCAATG-39
P-59/56-FAM/CAGCCCGTT/ZEN/CCGCAGAAAGC/3IABkFQ/-39
mFcRn NM_010189 F-59-CGTTCTTGGTTTATTGCTGGTG-39
R-59-CAACAGGTCACCAGAGTCATC-39
P-/56-FAM/CCCCATGGC/ZEN/TTTCTCTCAGCGG/3IAkFQ/-39
mouse polyubiquitin B (Ubb) NM_011664.3 F-59-TCTTTCTGTGAGGGTGTTTCG-39
R-59-GTTCTCGATGGTGTCACTGG-39
P-59-/56-FAM/CTAGGGTGA/ZEN/TGGTCTTGCCGGTC/3IABkFQ/-39
doi:10.1371/journal.pone.0036286.t001
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containing 0.05% Na-azide) onto glass slides covered with a
nitrocellulose membrane in a two-pad format compatible with
Whatman FAST Slide incubation chambers. Mouse IgG, goat
anti-mouse IgG (Jackson ImmunoResearch Laboratories, New-
market, Suffolk, UK), goat anti-mouse IgM (Jackson ImmunoR-
esearch Laboratories), mouse serum, and mouse albumin were
printed at different dilutions as internal and interassay controls.
Features were printed in triplicates at a density of 100 spots/cm
2
and with a diameter of approximately 400 mm using the
BioOdyssey Calligrapher miniarrayer (BioRad, Hercules, CA,
USA). Slides were stored at 4uC in sealed bags until use.
Testing serum samples
Samples collected on day 49, one week after the last
immunization, were tested individually on microarrays. Pooled
samples were prepared on days 21, 28, 42 and 49 and tested to
determine the dynamics of the humoral immune response of the
animals. Slides were put into Whatman FAST Slide incubation
chambers and washed 36 for 10 min with PBS on an orbital
shaker. The slides were then blocked with dilution buffer (PBS
containing 25 mM EDTA, 5% BSA, and 0.05% Tween-20) for
1 hour and washed with PBS-Tween for 10 min. Slides were then
incubated with sera diluted in dilution buffer (1:25 for IgM and
1:2500 for IgG measurements) at 37uC for 1 hour, washed twice
for 10 min with PBS-Tween and pulled out of the incubation
chambers. 7 ml of diluted goat Cy5-labeled anti-mouse IgG
(SouthernBiotech, Birmingham, AL, USA) (1:5000) or FITC-
labeled rat anti-mouse IgM (eBioscience) (1:2500) were added for
30 minutes at RT. Slides were washed twice for 10 min with PBS-
Tween and spun dry.
Scanning and data analysis
Microarrays were scanned with the Axon GenePix 4200A
(Molecular Devices, Sunnyvale, CA, USA) equipped with GenePix
Pro 7.0 (Molecular Devices, Corp.) software on 25% power, 530
PMT gain and 20 mm pixel size. Fluorescence intensity was
calculated for each spot as the median fluorescence of the feature
minus the fluorescence of the local background. The signal was
considered positive when the fluorescence intensity of the spot was
higher than the average fluorescence intensity of printed
streptavidin. For interassay comparison, data were normalized to
the mean fluorescence intensity of control samples, which consist
of mouse IgG in the case of IgG measurements and total mouse
serum for IgM measurements.
Results
bFcRn a-chain is strongly expressed in peritoneal
macrophages and bone marrow derived dendritic cells of
the bFcRn Tg mouse
Our previous studies of the bFcRn Tg mice revealed that
overexpression of the bFcRn leads to a general increase in
secondary humoral immune response, in addition to the increase
in serum IgG levels. To further understand this effect, we have
investigated the expression profile of the bFcRn transgene in
splenic B cells and T cells, as well as in peritoneal macrophages,
bone marrow derived dendritic cells and peritoneal neutrophil
granulocytes at protein and mRNA levels.
Expression at protein level. Expression at protein level
spleen, B cells (99.4% purity), T cells (99.5% purity), peritoneal
neutrophil granulocytes (91.4% purity), bone marrow derived
dendritic cells (97.8% purity), and peritoneal macrophages (99.3%
purity) were isolated from non-immunized bFcRn Tg animals.
The expression of bovine a-chain protein was analyzed by
Western blot using our newly developed monoclonal antibody
1E5/2. Based on its molecular weight, the 38-kDa band was
specific for bFcRn as also evidenced by its expression in the bFcRn
stable transfected cells (B4) [23] for positive and the spleen sample
from a control BALB/c mouse as negative control, respectively
(which also indicated that our 1E5/2 mAb does not cross react
with mFcRn a-chain). Blot was stripped and rehybridized with an
anti-b-actin monoclonal antibody as a loading control. We
detected strong bFcRn a-chain protein expression in
macrophages and dendritic cells of bFcRn Tg mouse. Tg spleen
showed a-chain protein expression, too, however its expressional
level was much lower compared to the macrophages and dendritic
cells. Since the bFcRn expressional level was undetectable in B-
cells and T-cells that dominates the non-immunized spleen or in
neutrophil granulocytes, the weak bFcRn expression in spleen
probably reflects bFcRn expression in the splenic macrophages
and dendritic cells (Figure 1A).
Expression at mRNA level. Expression at mRNA level we
also analyzed the expression ratios of the bFcRn to mFcRn at
mRNA level in peritoneal macrophages (99.3% purity), bone
marrow derived dendritic cells (97.8% purity) and spleen from
bFcRn Tg mice with a quantitative real-time PCR assay. We
found that the bFcRn expression was 3.8-, 2.6- and 10-fold higher
compared to the expression of the mFcRn in spleen, macrophages
and dendritic cells, respectively (Figure 1B). This dataset
indicates a significantly higher level expression of the bFcRn
than its mouse counterpart due to the fact that these Tg mice carry
and efficiently express 5 copies of the bFcRn transgene. The more
robust bFcRn expression in the bone marrow derived dendritic
cells is probably the result of the cytokine stimulus (IL-4, GM-CSF)
used to generate these cells.
FcRn overexpression leads to an increase in OVA-IgG
immune-complex phagocytosis
We next investigated the effects of FcRn overexpression in the
phagocytic activity of APCs. We isolated peritoneal macrophages
and differentiated bone marrow-derived dendritic cells from
bFcRn Tg and wt mice and performed an in vitro phagocytosis
assay using an Alexa Fluor 488-labeled OVA-IgG immune
complex (IC) or Alexa Fluor 488-labeled OVA alone. We found
that both the peritoneal macrophages (CD11b
+Gr1
2) and the
bone marrow DCs (MHCII
+CD11c
+CD11b
+) derived from
bFcRn Tg mice have significantly higher phagocytic activity than
the corresponding cells from wt mice (Figure 2A and B). We
confirmed the intracellular localization of the phagocytosed ICs by
confocal microscopy (Figure 2C). We have not detected any
difference in the cell surface expression of the FccRs, MHC class
II and B7.1, B7.2 molecules on the Tg and wt dendritic cells (data
not shown).
Bone marrow-derived DCs from bFcRn Tg mice have
enhanced Ag presentation ability
To determine whether the increase in phagocytic activity of
bone marrow-derived DCs correlates with a higher Ag presenting
ability, we performed an Ag-specific T-cell proliferation assay. We
found that bone marrow-derived DCs from bFcRn Tg mice
loaded with OVA-IgG IC induce significantly higher CD4
+ T-cell
proliferation as compared to bone marrow-derived DCs from wt
mice (Figure 2D). No differences were observed in the levels of
stimulation of T cell proliferation by Tg and wt bone marrow-
derived DCs loaded with soluble OVA alone (Figure 2D).
APC Activity and Ab Diversity in bFcRn Tg Mice
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over time in Tg mice
As previously reported, bFcRn Tg mice produce three times
more OVA-specific IgG than wt mice ([18] and data not shown)
and the augmented antigen-specific humoral immune response in
Tg mice results in larger numbers of antigen specific B cells
[18,19,20]. To investigate whether the higher levels of antibody in
bFcRn Tg mice correlate with an increase in the diversity of
recognized peptides, we used microarrays containing a library of
overlapping peptides that cover the whole sequence of OVA.
These microarrays allow for the identification of linear epitopes
recognized by antibodies present in the serum of immunized mice.
First, we investigated the effects of FcRn overexpression on the
overall dynamics of the humoral immune response. Sera from 15
bFcRn Tg (red) and 15 wt mice (blue) were collected on days 21,
28, 42 and 49 after immunization, pooled, and tested on the OVA
peptide microarrays. On day 21 (secondary immune response),
both wt and bFcRn Tg mice produced IgM that recognized
several peptides in the microarrays, albeit with low signal intensity.
In wt mice, there was little change in the levels of peptide-specific
IgM throughout the entire immunization protocol. In contrast, the
Tg mice produced continuously increasing amounts of epitope-
specific IgM Abs, which in several cases, reached their highest
signal intensity on day 49 (Figure 3). The amount of peptide-
specific IgGs increased over time in both groups, with a more
robust increase in Tg mice in some peptides (Figure 4).
bFcRn Tg mice show increased levels and higher diversity
of IgM than wt mice
To investigate the individual variation within the group of Tg or
wt mice, serum collected from each mouse on day 49 was
individually tested on OVA peptide microarrays. First, we
examined whether overexpression of bFcRn affects the diversity
of IgM. We performed epitope mapping of IgM from sera
collected on day 49 and observed clear differences between the
groups of Tg and wt mice. All of the individual Tg mice displayed
significantly higher levels and diversity of IgM as compared to wt
mice (Figure 5). We observed that all the peptides recognized by
IgG (Figure 6) were also recognized by IgM. A larger number of
individuals from the bFcRn Tg group produced IgM against a
given peptide and, consequently, the cumulative signal intensity
for each peptide was much higher for the Tg animals as compared
to the wt controls (Figure 5).
Several peptides that were not recognized by IgG from neither
Tg nor wt mice were positive for IgM produced by bFcRn Tg
mice (Figure 7). The bFcRn Tg mice showed significantly higher
diversity and levels of IgM, displaying positive signals to several
peptides (e.g., 32, 33, 44 53, 69, 74, 93 and 94), while the wt mice
showed minimal or no signal for these peptides (Figure 5 and 7).
Analyzes of individual samples revealed the diversity of peptide-
specific IgM Abs, which was not seen in the pooled sera (Figure 3).
bFcRn Tg mice produce higher levels of epitope-specific
IgGs than wt mice
Next, we analyzed whether overexpression of bFcRn affects the
diversity of IgG. The number of animals that show a positive
signal for a given peptide was highly variable in both groups.
Almost all animals produced IgG that recognized peptides 15 and
57, while approximately half of the animals from each group had
IgG to peptides 16, 48 and 62. Some OVA peptides were only
recognized by IgG from a small number of Tg and wt mice
(Figure 6). Cumulative signal intensities were calculated for each
peptide to determine the overall antibody production against
specific epitopes in the two groups. Data show that the majority of
peptides recognized in both groups have higher cumulative
intensity in the Tg group (Figure 6).
Discussion
Over the last 35 years, mAbs have become an essential tool for
clinical research and have been increasingly used for the diagnosis
and treatment of malignant, inflammatory, autoimmune and
infectious diseases. Despite the recent development of alternative
methods to generate recombinant antibodies, such as in vitro
display technologies, murine hybridoma technology is still the
most widely employed method for producing mAbs. In order to
screen and produce effective antibodies with high affinity and
Figure 1. bFcRn is strongly expressed in bone marrow derived dendritic cells and peritoneal macrophages of bFcRn Tg mice. A.
Western blot analysis shows the expression of bovine a-chain protein in spleen (TgS), B cells (B, 99.4% purity), T cells (T; 99.5% purity), peritoneal
neutrophil granulocytes (Ne; 91.4% purity), bone marrow derived dendritic cells (DC; 97.8% purity), and peritoneal macrophages (MW; 99.3% purity)
from non-immunized bFcRn Tg animals. Based on its molecular weight, the 38-kDa band was specific for bFcRn as also evidenced by its expression in
the bFcRn stable transfected cells (B4) [23] for positive and spleen (WtS) from a control BALB/c mouse as negative control, respectively (which also
indicates that our bFcRn specific 1E5/2 mAb does not cross react with mFcRn a-chain). Blot was stripped and rehybridized with an anti-b-actin
monoclonal antibody as a loading control. B. Expression ratios of the bFcRn to mFcRn at mRNA level in peritoneal macrophages (MW; 99.3% purity),
bone marrow derived dendritic cells (DC; 97.8% purity) and spleen from bFcRn Tg mice analyzed with a quantitative real-time PCR assay. We found
that the bFcRn expression was 3.8-, 2.6- and 10-fold higher compared to the expression of the mFcRn in spleen, macrophages and dendritic cells,
respectively. Results are representative of 3 independent experiments and show as the mean 6SD.
doi:10.1371/journal.pone.0036286.g001
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especially to generate functionally relevant mAbs that bind native
epitopes and can be used for therapeutic approaches [2].
However, some challenges remain to improve the efficiency of
clone generation. For example, the number of B cells secreting a
specific antibody can be as low as 1% of the total number of
lymphocytes in an immunized mouse. The efficiency of fusion of
splenocytes and myeloma cells is also very low and only a small
number of fused cells are able to grow as hybridomas during
selection [25]. Finally, the stability of the generated clones is also
uncertain and a large fraction of hybridomas stop secreting over
time, due to random shedding of chromosomes until they reach a
stable genomic configuration [26].
Our group has recently generated Tg mice overexpressing the
bFcRn gene, which show a significant increase in the levels of
serum IgG and IgM in response to a variety of Ags without
presenting any signs of autoimmunity [3,18,19,20]. We also
observed that the bFcRn Tg mice develop enlarged spleens
containing increased numbers of neutrophil granulocytes, den-
dritic cells, Ag-specific B cells and plasma cells, which allow for a
significantly improved efficiency of hybridoma production [19]. In
parallel with this study, we have recently tested whether the bFcRn
Tg mice would yield specific antibodies against a clinically
relevant, yet weakly immunogenic target. In that study, we
immunized both Tg and wt mice with the human chemokine
receptor CXCR4, which belongs to the G protein-coupled
receptor (GPCR) family and plays important roles in the
metastatic spread of cancer cells as well as in the entry of HIV
in CD4+ cells [27,28]. Using cells transfected with CXCR4 as the
immunogen, we were able to isolate four anti-CXCR4 positive
Figure 2. bFcRn-expressing cells show enhanced IC phagocytosis and induce higher T cell proliferation. (A) Peritoneal macrophages
(MW) and (B) bone marrow-derived dendritic cells (DC) isolated from bFcRn Tg and wt mice were incubated with Alexa Fluor 488-conjugated OVA-
IgG immune complex (IC) or with Alexa Fluor 488-conjugated OVA (OVA) alone at 37uC for the indicated times. As negative controls, cells were left on
ice for 30 minutes in the presence of either IC or OVA. The uptake was analyzed by flow cytometry using anti-CD11b-Alexa Fluor 647 and anti-Gr1
(Ly6-G)-PE as markers for macrophages, and anti-MHCII (I-A/I-E)-PE and anti-CD11b-Alexa Fluor 647 for dendritic cells. The results are expressed in
RMF (relative mean fluorescence). Values shown are the means 6 SD (*, P,0.05; **, P,0.01; ***, P,0.001). The experiments were repeated three
times, with three parallels with similar results. (C) Peritoneal macrophages (MW) from bFcRn Tg and wt mice were incubated with Alexa Fluor 488
conjugated OVA-IgG (green) at 37uC for 60 min. Cells were then washed, labeled with Alexa Fluor 647-conjugated anti-CD11b (red) and visualized by
confocal microscopy. (D) Bone marrow-derived dendritic cells (DC) from wt and bFcRn Tg mice were left untreated or loaded with either OVA-IgG
immune complex (IC) or OVA alone for 1 hour at 37uC and 5% CO2. CD4+ T cells from OVA TCR (DO11.10) Tg mice were then added to both the
untreated and loaded DCs. After 24 hours, proliferating T cells were labeled for 12 h with [H3]-thymidine. As a positive control, CD4+ T cells were
incubated with Concavalin A (ConA). Results are representative of 3 independent experiments and show as the mean 6SD (*, P,0.05; **, P,0.01;
***, P,0.001).
doi:10.1371/journal.pone.0036286.g002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36286Figure 3. bFcRn Tg mice show higher levels and increased diversity of peptide-specific IgM at 21, 28, 42 and 49 days after initial
OVA immunization. Sera from 15 bFcRn Tg (red) or 15 wt (blue) mice immunized with OVA were collected on the indicated days, pooled and
tested on OVA overlapping peptide microarrays. IgMs bound to different peptides were detected with rat anti-mouse IgM conjugated to FITC and the
fluorescence intensity was calculated for each spot as the median fluorescence of the spot minus the fluorescence of the local background. Numbers
on the X-axis refer to the specific OVA peptide on the microarray slide.
doi:10.1371/journal.pone.0036286.g003
Figure 4. bFcRn Tg mice show increased levels of epitope-specific IgGs. Sera from 15 bFcRn Tg (red) or 15 wt (blue) mice immunized with
OVA were collected on the indicated days, pooled and tested on OVA overlapping peptide microarrays. IgGs bound to different peptides were
detected with a goat anti-mouse IgG conjugated to Cy5 and the fluorescence intensity was calculated for each spot as the median fluorescence of
the spot minus the fluorescence of the local background. Numbers on the X axis refer to the specific OVA peptide on the microarray slide.
doi:10.1371/journal.pone.0036286.g004
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animals did not produce a single CXCR4-specific clone [29]. In
addition, one of the four CXCR4-specific mAbs binds a
functionally relevant epitope on this receptor as it inhibits the
binding of a well characterized CXCR4-specific mAb (12G5) [30].
In our recent publications, we proposed that overexpression of
bFcRn leads to a better protection of the Ag-specific IgGs which,
in turn, can generate a greater amount of Ag-IgG ICs. The ability
of ICs to induce potent humoral immune responses has long been
known [31,32,33,34]. We found that immunization significantly
increases the number of neutrophil granulocytes in the spleen and
that this change is more pronounced in Tg animals than in the wt
controls [18,20]. This is consistent with other recent observations
indicating that, in the presence of Ag-IgG ICs, neutrophils are the
main Ag-specific cells recruited to draining lymph nodes and that
their numbers depend on the levels of ICs [35,36,37]. Since the
bFcRn Tg mice have higher levels of Ag-specific IgGs than wt
mice, we concluded that the difference in the numbers of
neutrophils in Tg and wt mice can be explained, at least in part,
by the presence of higher levels of Ag-IgG ICs formed and/or
transported by neutrophils in Tg animals. Furthermore, it has
been shown that FcRn is expressed in neutrophils and plays an
active role in Ag-IgG IC phagocytosis [13]. We have recently
shown that FcRn overexpression in neutrophils of bFcRn Tg mice
results in more efficient phagocytosis [18], which further boosts
their activation, and contributes to their increased influx into the
draining secondary lymphoid tissues or spleen. The emerging
evidence of the important and multifaceted roles of neutrophil
granulocytes in potentiating the adaptive immune response in
secondary lymphoid organs have been recently reviewed [38].
We also found that immunization leads to a significant increase
in the number of dendritic cells in the spleen and that this change
was, similarly to that observed for neutrophils, more striking in
bFcRn Tg animals as compared to wt mice [18,20]. Recent studies
have shown that FcRn is expressed in APCs [10,15,39] and
efficiently increases phagocytosis and recycling of monomeric IgG
in these cells. In addition, FcRn was found to direct Ag-IgG ICs
into lysosomes and to play a role in Ag presentation and humoral
immune responses [14,15,16,17]. Taken together, the data
indicate that FcRn redirects Ags complexed with IgG into
degradative compartments that are associated with the loading
of antigenic peptides onto MHC class II molecules within cells [8].
The larger number of dendritic cells observed in bFcRn Tg
animals after immunization suggests that these mice have higher
Ag-presenting capability than wt mice [18,20].
In this current study, we also addressed whether the APCs from
bFcRn Tg mice, including macrophages, dendritic cells and B
cells, express the bFcRn transgene and if they do, how this
expression affects their phagocytic and Ag presentation abilities.
Our results indicate that the elevated immune response observed
in bFcRn Tg mice could be the result of the increased
phagocytosis capacity and enhanced Ag-presenting ability of
macrophages and dendritic cells overexpressing the bovine FcRn
transgene. As shown, the transgenic bFcRn is strongly expressed in
macrophages and dendritic cells (Figure 1A and 1B), resulting in
the enhanced processing of phagocytosed ICs and more effective
Figure 5. bFcRn Tg mice show increased levels and higher diversity of epitope-specific IgM as compared to wt mice. Sera from 15
bFcRn Tg (red) and 15 wt (blue) mice immunized with OVA were collected on day 49 and tested individually on microarrays containing 95
overlapping 12-mer peptides that cover the whole sequence of ovalbumin. IgMs bound to different peptides were detected with a rat anti-mouse
IgM conjugated to FITC and the fluorescence intensity was calculated for each spot as the median fluorescence of the spot minus the fluorescence of
the local background. Numbers on the X axis refer to the specific OVA peptide in the microarray. For comparison between assays, the data were
normalized to the mean fluorescence obtained for whole serum of a naı ¨ve mouse. The cumulative data represents the addition of all the fluorescence
intensity values obtained for each peptide-specific IgG from bFcRn Tg or wt mice on day 49.
doi:10.1371/journal.pone.0036286.g005
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transgene in these two cell types is consistent with the expression of
its mouse counterpart, i.e. mFcRn expression is similarly highly
expressed in macrophages and dendritic cells as it has been shown
by gene expression analysis performed by others (Immunological
Genome Project; www.immgen.org). This suggests that the
regulatory sequences of the bFcRn a-chain gene are properly
regulated by the endogenous transcriptional machinery of the
mouse. The higher expression ratio of the bFcRn to mFcRn in the
bone marrow derived dendritic cells suggests that the bFcRn
expression is strongly stimulated by IL-4 and/or GM-CSF, while
these factors may not induce such a strong influence for the
mFcRn expression. We currently analyze the transcriptional
regulation of the bFcRn a-chain to further elucidate this exciting
observation. Although previous work of others and our own study
indicated FcRn expression in neutrophil granulocytes [13,18] and
B cells [15] we did not detect bFcRn expression at protein level in
Western blot (Figure 1A). Perhaps a more sensitive method
(confocal microscopy, FACS) would detect this protein in these cell
types.
Our study revealed that the macrophages and dendritic cells
from Tg animals have a significant increase in their phagocytic
activity (4-fold in dendritic cells) (Figure 2A–C) and induce 6-fold
higher proliferation of CD4
+ T cells (Figure 2D). Since we did
not detect any difference in the cell surface expression of the
FcgRs, MHC class II, B7.1 and B7.2 between Tg and wt dendritic
cells, the increased T cell proliferation was probably the result of
the greater proportion of MHC class II loaded with OVA derived
peptides in case of bFcRn Tg cells. The enhanced activation of T
helper cells may also contribute to the elevated secondary humoral
response and the increased diversity of Abs observed in
immunized bFcRn Tg mice.
It is possible that the more efficient Ag presentation in bFcRn
Tg mice (Figure 2D) results in a more robust activation of the
existing Ag-specific memory B cells, which would explain the
higher levels of Ag-specific IgG in the bFcRn Tg mice observed
previously [18,20] and also in this study (Figure 4, 6). In addition,
a recent report demonstrated that the ICs formed between Ags
and pre-existing Abs from the primary immune response activate
naı ¨ve B cells, inducing them to respond with accelerated kinetics
and increased magnitude during the secondary immune response
[40,41]. In bFcRn Tg mice, overexpression of bovine FcRn leads
to an increase in the half-life of IgG, which remain in the
circulation and form ICs upon secondary exposure to the Ag.
These ICs induce a higher proliferation of Ag-specific memory B
cells and the activation of naı ¨ve B cells, resulting in a synergistic
enhancement of the secondary humoral immune response.
Encouraged by experimental results that consistently demon-
strate a superior immune response capability in FcRn overex-
pressing animals; we investigated the diversity of OVA induced
Abs in Tg and wt mice using microarray-based oligopeptide
scanning. The microarrays used in our study contained a library of
overlapping peptides covering the whole sequence of OVA,
similarly to a previously described method [42]. Although the
majority of Ag-Ab interactions are based on conformational
epitopes and oligopeptide scanning only allows for the identifica-
tion of linear epitopes, this method is best suited to map epitopes
from a large population of Abs generated against a defined target.
We observed that the number of epitopes recognized by IgM is
substantially increased in bFcRn Tg mice (Figure 5), suggesting
that a significantly greater number of naı ¨ve B cells are activated in
Tg mice as compared to the wt controls. We also detected
significantly higher titers of peptide-specific IgG in Tg mice,
however the epitopes targeted by IgG are similar between the two
Figure 6. bFcRn Tg mice show higher levels of epitope-specific IgGs as compared to wt mice. Sera from 15 bFcRn Tg (red) and 15 wt
(blue) mice immunized with OVA were collected on day 49 and tested individually on microarrays containing 95 overlapping 12-mer peptides that
cover the whole sequence of ovalbumin. IgGs bound to different peptides were detected with a goat anti-mouse IgG conjugated to Cy5 and the
fluorescence intensity was calculated for each spot as the median fluorescence of the spot minus the fluorescence of the local background. Numbers
on the X axis refer to the OVA peptide in the microarray. For comparison between assays, the data were normalized to the mean fluorescence of
purified mouse IgG. The cumulative data represents the addition of all the individual fluorescence intensity values obtained for each peptide-specific
IgG from either bFcRn Tg or wt mice.
doi:10.1371/journal.pone.0036286.g006
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augmented immune response in the Tg mice results in larger
numbers of Ag-specific B cells [18,19,20], we propose that a larger
number of memory B cells is activated in these Tg mice in case of
at least some of the recognized epitopes. Whether the more B cells
recognizing a given peptide originate from more clones leading to
greater diversity in Tg animals remains to be determined
(Figure 6).
It is well-known that the immune system, with its ability to
recognize a wide array of B- and T cell epitopes, can exhibit a
strong preference for a limited set of epitopes. An earlier study
showed that immunization with oligopeptides generates a multi-
specific IgM response, whereas the mature IgG response was
found to focus primarily on one tetrapeptide sequence (immuno-
dominant epitope) [43]. Interestingly, the selection for mono-
specificity occurs at or around the time of IgM to IgG class switch
and is only reflected in the IgG population. Yet, when
immunodominant epitopes are removed from the Ag, IgG are
produced against other potentially antigenic determinants [43].
Thus, it is possible to refocus antibody response by targeted
dampening of an immunodominant epitope [44,45,46]. This
suggests that immunodominant epitopes can block effective
immune response to subdominant epitopes even when the immune
response is significantly augmented as in the case of the bFcRn Tg
mice.
Whereas the enhancement of epitope recognition in FcRn-
overexpressing animals is most compelling at the IgM level, the
translation from IgM to IgG appears to be suppressed by
immunodominant epitopes present on OVA. However, the
observation of the much augmented immune response displayed
by FcRn Tg mice is consistent with our findings of significantly
elevated IgG quantities in this paper (approximately 3-fold higher
titers of IgG in FcRn Tg mice than in wt). These results are also in
line with our previous reports describing a substantial increase in
the levels of Ag-specific IgG in FcRn Tg mice immunized with Ags
that are weakly immunogenic in wt mice and, therefore, not
affected by immunodominance, including a conserved influenza
hemagglutinin (HA) peptide [20] and human CXCR4 [29].
Experiments with a series of other Ags, which cannot induce a
meaningful immune response in standard models, are currently
being done by our group and by other independent parties. To the
best of our knowledge no other method has been described to date
which shows a similar capability to augment the immune response
both by qualitative as well as by quantitative measures.
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